ArticleBritish journal of cancer2012
Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway.
Article in British journal of cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A systematic review of economic evaluations of cervical cancer screening methods.Systematic reviews · 2022Pooled it
- Systematic review of cost-effectiveness analyses for combinations of prevention strategies against human papillomavirus (HPV) infection: a general trend.BMC public health · 2017Pooled it
- Randomized Implementation of a Primary Human Papillomavirus Testing-based Cervical Cancer Screening Protocol for Women 34 to 69 Years in Norway.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Trial
- Cost-effectiveness analysis of primary human papillomavirus testing in cervical cancer screening: Results from the HPV FOCAL Trial.Cancer medicine · 2021Trial
- How does information on the harms and benefits of cervical cancer screening alter the intention to be screened?: a randomized survey of Norwegian women.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2019Trial
- Evaluating the Cost-Effectiveness of Cervical Cancer Screening and Treatment in Western Romania.Current oncology (Toronto, Ont.) · 2025Article
- Performance of HPV genotyping andFrontiers in medicine · 2025Article
- Fine-grained mathematical modeling for cost-effectiveness evaluation of public health policies for cervical cancer, with application to a Colombian case study.BMC public health · 2023Article
- Follow-up study on ThinPrep cytology test-positive patients in tropical regions.World journal of clinical cases · 2022Article
- Cervical Cancer Screening with HPV Testing: Updates on the Recommendation.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2022Article
- Cervical cancer in Nepal: Current screening strategies and challenges.Frontiers in public health · 2022Review
- Reducing Poverty-Related Disparities in Cervical Cancer: The Role of HPV Vaccination.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021Article
- Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an example: A modelled analysis.Preventive medicine · 2021Article
- Uptake of co-testing with HPV and cytology for cervical screening: A population-based evaluation in the United States.Gynecologic oncology · 2021Article
- Screen, Notify, See, and Treat: Initial Results of Cervical Cancer Screening and Treatment in Rwanda.JCO global oncology · 2021Article
- Cost-effectiveness of HPV-based cervical screening based on first year results in the Netherlands: a modelling study.BJOG : an international journal of obstetrics and gynaecology · 2021Article
- Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen-detected cervical precancer.International journal of cancer · 2021Article
- Is the HPV-test more cost-effective than cytology in cervical cancer screening? An economic analysis from a middle-income country.PloS one · 2021Article
- Cost-effectiveness of cervical cancer screening with primary HPV testing for unvaccinated women in Sweden.PloS one · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundNew screening technologies and vaccination against human papillomavirus (HPV), the necessary cause of cervical cancer, may impact optimal approaches to prevent cervical cancer. We evaluated the cost-effectiveness of alternative screening strategies to inform cervical cancer prevention guidelines in Norway.
methodsWe leveraged the primary epidemiologic and economic data from Norway to contextualise a simulation model of HPV-induced cervical cancer. The current cytology-only screening was compared with strategies involving cytology at younger ages and primary HPV-based screening at older ages (31/34+ years), an option being actively deliberated by the Norwegian government. We varied the switch-age, screening interval, and triage strategies for women with HPV-positive results. Uncertainty was evaluated in sensitivity analysis.
resultsCurrent cytology-only screening was less effective and more costly than strategies that involve switching to primary HPV testing in older ages. For unvaccinated women, switching at age 34 years to primary HPV testing every 4 years was optimal given the Norwegian cost-effectiveness threshold ($83,000 per year of life saved). For vaccinated women, a 6-year screening interval was cost-effective. When we considered a wider range of strategies, we found that an earlier switch to HPV testing (at age 31 years) may be preferred.
conclusionsStrategies involving a switch to HPV testing for primary screening in older women is expected to be cost-effective compared with current recommendations in Norway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.